{"metadata":{"topics":["Acceleration","Access to information","Accountability","Accredited investor","Administrative law","Agencies of the United States government","Applied ethics","Armenia","Asia","Asset","Assignment (law)","Attorney's fee","Attorney–client privilege","Audit","Bank","Blue sky law","Board of directors","Broker","Broker-dealer","Business","Business economics","Business law","Business organizations","Cadwalader, Wickersham & Taft","Capital (economics)","Chairman","Chief executive officer","Chief financial officer","China","Civil law (common law)","Civil law (legal system)","Cognition","Cognitive science","Common law","Common stock","Communication","Companies","Companies of the United States","Company","Comparative law","Compensation and benefits","Confidentiality","Conflict (process)","Conflict of interest","Consent","Consolidation (business)","Contract","Contract law","Corporate finance","Corporate governance","Corporate jargon","Corporate law","Corporate personhood","Corporation","Corporations","Corporatism","Court","Court orders","Covenant (biblical)","Covenant (law)","Criminal justice","Criminal law","Culture","Currency","Custom","Damages","Data","Directors and officers liability insurance","Disability","Discovery (law)","Dividend","Doctrines","Document","Documents","Dollar","Economic law","Economics","Economies","Economy","Economy of the United States","Email","Email address","Employee benefits","Employment","Equity (law)","Equity securities","Ethical principles","Ethics","Evidence","Exchange rate","Exercise","Expense","Factor income distribution","Failure","Faith","Fax","Federal government of the United States","Fee","Finance","Financial Industry Regulatory Authority","Financial accounting","Financial crime prevention","Financial economics","Financial law","Financial markets","Financial regulation","Financial regulatory authorities","Financial risk","Financial services","Financial statement","Financial statements","Financial transaction","Form 10-K","Form 10-Q","Form 8-K","Form S-1","Form S-3","Free trade","Glossary of patent law terms","Good faith","Governance","Government","Government agencies","Government and personhood","Government information","Government institutions","Government of the United States","Government-related organizations","Haikou","Hainan","Health","Human activities","Human rights","Incentive","Indemnity","Independent agencies of the United States government","Industry","Information","Information science","Initial public offering","Injunction","Insurance","Intellectual works","Interest","International law","International relations","Investment","Investment banking","Investment fund","Investment management","Investor","Issuer","Jargon","Jianguo Road (Beijing)","Judicial remedies","Judiciaries","Jurisdiction","Jurisprudence","Justice","Knowledge","Law","Law and economics","Law of obligations","Lawyer","Leadership","Lease","Legal communication","Legal concepts","Legal doctrines and principles","Legal documents","Legal ethics","Legal fictions","Legal liability","Legal procedure","Legal remedy","Legal writing","Liability (financial accounting)","Liability insurance","Love","Management","Market (economics)","Marketing","Matter","Mergers and acquisitions","Microeconomics","Misrepresentation","Money","Morality","National security","Nevada","Nevada corporation","New Deal agencies","Official documents","Omission (law)","Open government","Opinion","Option (finance)","Order (exchange)","Organization","Out-of-pocket expense","Ownership","PDF","Par value","Paragraph","Payment","Payments","Percentage","Personality traits","Philosophy","Political economy","Political science","Politics","Politics of the United States","Practice of law","Preferred stock","Price","Principles","Private law","Pro rata","Professional ethics","Property","Property law","Prospectus (finance)","Proxy statement","Public administration","Public finance","Public law","Public policy","Public policy doctrine","Public sphere","Quantity","Question","Questionnaire","Ratio","Reason","Receipt","Registration statement","Regulation","Regulation D (SEC)","Regulators","Regulatory compliance","Retirement","Right of first refusal","Rights","Risk","Roman law","Rules","Securities (finance)","Securities Act of 1933","Securities and exchange commissions","Securities regulation in the United States","Security","Security (finance)","Separation of powers","Service industries","Service of process","Services (economics)","Severability","Share (finance)","Shareholder","Short (finance)","Signature","Social institutions","Social issues","Sociological theories","Sources","Specific performance","Staff (military)","State Security Law in Bahrain","Statutory law","Stock","Stock market","Stock split","Stock transfer agent","Subpoena","Subsidiary","Synergy","Tax","Tax return (United States)","Technology","Telephone","Theories of law","Tort of deceit","Trade","U.S. Securities and Exchange Commission","Understanding","Underwriting","United States","United States administrative law","United States business law","United States dollar","United States economic policy","United States federal policy","United States law","United States legislation","United States regulations","United States securities law","Value (ethics)","Virtue","Void (law)","Waiver","Warrant (finance)","Witness","Writing","Written communication"],"person_names":["deadline","holder","jiannan zhang","orbimed","orbimed designee","xueyun cui"],"vars":{"Party":{"Kun Run Biotechnology, Inc.":"[[Party 1]]"}},"organization_names":["blue sky","caduceus asia partners","cadwalader, wickersham & taft","commission","company register registrable securities","company the holders","d&o insurance","effectiveness deadline","finra corporate financing department","holders","holders of registrable securities","holders own registrable securities","new registration statements","other securities","registrable securities","securities purchase","state"],"agreement_id":"c27f012394945a9756fca37a206d69d3c66d9a17dac4e6eb10c760effce2b174","terms":["*******","**/s/ Xueyun Cui**","**Amendments and Waivers**","**Annex A**","**Board of Directors**","**Caduceus Asia Partners, LP**","**Conduct of Indemnification Proceedings**","**Contribution**","**Cumulative Remedies**","**Currency**","**D&O Insurance**","**Definitions**","**Discontinued Disposition**","**Entire Agreement**","**Execution and Counterparts**","**Further Assurances**","**Governing Law**","**Headings**","**Holder Covenants**","**Holders of Registrable Securities who do not complete, execute and return this Notice and Questionnaire within ten (10) Business Days following the date of the Agreement shall not be entitled to (1) be named as a selling stockholder in the Resale Registration Statement or the Prospectus or (2) use such Prospectus for offers and resales of Registrable Securities at any time.**","**INVESTOR RIGHTS AGREEMENT**","**Indemnification by Holders**","**Indemnification by the Company**","**Indemnification**","**Miscellaneous**","**NOTICE**","**No Senior Registration Rights**","**Notices**","**Other Agreements**","**PLEASE FAX A COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO:**","**Piggy-Back Registrations**","**Preemptive Rights**","**QUESTIONNAIRE**","**Qualified Auditor**","**Registration Expenses**","**Registration Procedures**","**Registration**","**Remedies**","**Right to Terminate Registration**","**SELLING STOCKHOLDER NOTICE AND QUESTIONNAIRE**","**Severability**","**Successors and Assigns**","**Suspension of Trading**","**Term**","**Transactions with Affiliates**","**Underwriting**","“***Advice***”","“***Affiliate***”","“***Agreement***”","“***Company***”","“***Effective Date***”","“***Effectiveness Deadline***”","“***Effectiveness Period***”","“***Excluded Securities***”","“***FINRA***”","“***Filing Deadline***”","“***Holder***”","“***Holders***”","“***Indemnified Party***”","“***Indemnifying Party***”","“***Independent Designee***”","“***Initial Registration Statement***”","“***Issuer Filing***”","“***Key Holder***”","“***Key Holder***” and, collectively, the “***Key Holders***”","“***Key Holders***”","“***Losses***”","“***New Registration Statement***”","“***Observer Rights***”","“***OrbiMed Designee***”","“***OrbiMed***”","“***Prospectus***”","“***Purchase Agreement***”","“***Purchaser***”","“***Purchasers***”","“***Register***","“***Registrable Securities***”","“***Registration Statements***”","“***Remainder Registration Statements***”","“***Resale Registration Statement***”","“***Rule 415***”","“***Rule 424***”","“***SEC Guidance***”","“***Selling Stockholder Questionnaire***”","“***Selling Stockholder***”","“***Special Registration Statement***”","“***Suspension Certificate***”","“***Suspension Period***”","“***Violations***”","“***registered***”","“***registration***”"]}}